USEOFSODIUMBEMIPARININOBSTETRICPRACTICE. A CLINICAL CASE
https://doi.org/10.17749/2313-7347.2017.11.3.094-097
Abstract
The report presents a case of pregnancy management in a woman with a history of obstetric problems and neurosensory hearing loss. After thorough hemostasis tests, the presence of antiphospholipid antibodies in the blood was detected. Given a high risk of thrombophilia in this situation, the patient was treated with antithrombotic therapy – low molecular weight heparin (sodium bemiparin).
About the Authors
D. Kh. Khizroeva
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Khizroeva Dzhamilya Hizrievna – MD, Professor, Department of Obstetrics and Gynecology, Faculty of Preventive Medicine.
Ul. Zemlyanoi val, 62, Moscow, 109004
D. V. Mitryuk
State Medical and Pharmaceutical University «Nicolae Testemitanu»
Russian Federation
Russian Federation
Mitryuk Diana Viktorovna – assistant, Department of Obstetrics and Gynecology.
Bul. Shtefan chel Mare, 165, Kishinev
References
1. Khizroeva J., Kapanadze D., Andreeva M., Abramyan G. Antiphospholipid antibodies circulation and fetal loss syndrome. Papers and Abstracts of the 6th International Symposium on Women’s Health Issues in Thrombosis and Haemostasis. February 13-5. Berlin, Germany. Thromb Res. 2015: 51.
2. Bitsadze V.O., Khizroeva D.Kh., Idrisova L.E., Abramyan R.R., Andreeva M.D., Makatsaria A.D. Catastrophic antiphospholipid syndrome. Questions of pathogenesis [Katastroficheskij antifosfolipidnyj sindrom. Voprosy patogeneza]. Akusherstvo, ginekologiya i reprodukciya. 2015; 9 (2): 32-53 (in Russian).
3. Heilmann L., Rath W. Thrombophilia in pregnancy. Bremen, London, New York: Unimed. 2002.
4. Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010; 29: 233-40.
5. Greer I.A., Nelson-Piercy C. Low-molecularweight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106 (2): 401-7.
6. Keeling D., Davidson S., Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006; 133: 259-69.
7. Baglin T., Barrowcliffe T.W., Cohen A., Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006; 133: 19-34.
8. Abbas M.S. Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients. Indian J Crit Care Med. 2017; 21 (7): 419-23. DOI: 10.4103/ijccm.IJCCM_23_17.
Review
For citations:
Khizroeva D.Kh., Mitryuk D.V. USEOFSODIUMBEMIPARININOBSTETRICPRACTICE. A CLINICAL CASE. Obstetrics, Gynecology and Reproduction. 2017;11(3):94-97. (In Russ.) https://doi.org/10.17749/2313-7347.2017.11.3.094-097
Views:
744
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
